zasocitinib
takeda
['tak-279', 'psoriasis']
results from a phase 2b trial indicate that the investigational drug tak-279 significantly improved clearance of skin lesions for patients with moderate to severe plaque psoriasis. #aad2023
SPC provides essential clinical and business information for owners and operators of specialty pharmacies, home infusion providers, insurers and MCOs.